Summary of Final Analysis from the MASTER Trial of DARA+KRd

Opinion
Video

Review of the final analysis of data from the MASTER clinical trial assessing daratumumab plus carfilzomib, lenalidomide and dexamethasone.

Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)

Clinical Presentation:

  • FH is a 54-year-old woman who presents to her physician with complaints of back pain, fatigue, nausea, constipation, and occasional, but recurring dizziness

Initial Clinical Workup and Diagnosis:

  • Hb 7.0 g/dL
  • Calcium 11.3 mg/dL
  • Creatinine, 1.5 mg/dL
  • Albumin, 3.2 g/dL
  • β2-microglobulin, 6.0 mg/dL
  • LDH 200 U/L
  • Bone marrow biopsy showed monoclonal plasma cells, 22%.
  • Serum monoclonal protein, 5.0 g/dL
  • Serum kappa FLC, 240.0 mg/L
  • FISH: (+) IGH Translocations; none
  • ECOG PS 1
  • AG was diagnosed with R-ISS stage II/R2-ISS stage III IgG-kappa myeloma.
    • CAR T eligible

Treatment:

  • Patient was initiated on daratumumab/bortezomib/ lenalidomide/ dexamethasone (D-VRd) induction therapy prior to receiving ASCT, followed by lenalidomide maintenance therapy.
    • She achieved VGPR post-induction, and
    • Maintained VGPR post-ASCT

This is a video synopsis/summary of a Case-Based Peer Perspective featuring: Douglas Sborov, MD.

The phase 2 MASTER trial investigated daratumumab, carfilzomib, lenalidomide, and dexamethasone (DKRd) in transplant-eligible newly diagnosed multiple myeloma. Patients received DKRd induction, autologous stem cell transplant, then 4 cycles of DKRd consolidation. Those achieving minimal residual disease (MRD) negativity twice discontinued treatment; others completed planned DKRd.

Postconsolidation MRD-negativity rates (10-5 threshold) were approximately 80% overall and in subgroups without high-risk cytogenetics, with 1 high-risk abnormality, and with ultra–high-risk disease. MRD-negativity rates (10-6 threshold) were 66% overall but lower in the ultra–high-risk subgroup. Three-year progression-free survival was 66% without high-risk features, 82% with 1 high-risk feature, and 63% with 2 or more high-risk features.

Key conclusions: DKRd is highly effective even in high-risk newly diagnosed transplant-eligible multiple myeloma. MRD-adapted therapy should be explored further in specific populations. Patients with 2 or more high-risk cytogenetic features need improved approaches.

Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.

Recent Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
1 expert in this video
1 expert in this video
Related Content